Mechanisms of thrombosis in pancreatic ductal adenocarcinoma.

Cancer-associated thrombosis Extracellular vesicles Hypercoagulability Tissue factor Venous thrombosis

Journal

Best practice & research. Clinical haematology
ISSN: 1532-1924
Titre abrégé: Best Pract Res Clin Haematol
Pays: Netherlands
ID NLM: 101120659

Informations de publication

Date de publication:
03 2022
Historique:
received: 16 05 2022
accepted: 19 05 2022
entrez: 27 8 2022
pubmed: 28 8 2022
medline: 31 8 2022
Statut: ppublish

Résumé

Patients with pancreatic cancer have a very high risk of both venous and arterial thrombosis compared with other cancers, caused by a tumour-driven hypercoagulable state. Better understanding of pancreatic cancer-associated prothrombotic and proinflammatory mechanisms opens the door to controlling prothrombotic states, ideally, without affecting the overall haemostasis. This narrative review brings together currently available evidence on epidemiology and pathogenesis of thrombotic complications in pancreatic adenocarcinoma. We describe risk factors for thrombosis and established and novel mechanisms of hypercoagulability. Among novel pathways of hypercoagulability, the release of neutrophils extracellular traps (NETs) by activated neutrophils and the crucial role of extracellular vesicles (EV) in participating in platelet and coagulation activation were described. We also reported recent evidence on EV role in thrombin generation amplification through the activation of the intrinsic pathway, discussing potential molecules implicated in this process.

Identifiants

pubmed: 36030065
pii: S1521-6926(22)00001-9
doi: 10.1016/j.beha.2022.101346
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

101346

Informations de copyright

Copyright © 2022 Elsevier Ltd. All rights reserved.

Auteurs

Elena Campello (E)

General Medicine and Thrombotic and Haemorrhagic Diseases Unit, Department of Medicine - DIMED, University of Padova, Padova, Italy. Electronic address: elena.campello@unipd.it.

Floris Bosch (F)

Department of Internal Medicine, Tergooi Hospitals, Hilversum, the Netherlands; Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers (UMC), University of Amsterdam, Amsterdam, the Netherlands.

Chiara Simion (C)

General Medicine and Thrombotic and Haemorrhagic Diseases Unit, Department of Medicine - DIMED, University of Padova, Padova, Italy.

Luca Spiezia (L)

General Medicine and Thrombotic and Haemorrhagic Diseases Unit, Department of Medicine - DIMED, University of Padova, Padova, Italy.

Paolo Simioni (P)

General Medicine and Thrombotic and Haemorrhagic Diseases Unit, Department of Medicine - DIMED, University of Padova, Padova, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH